Roche Introduces CoaguChek Link Web Resource

INDIANAPOLIS, Nov. 8, 2010 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY)

and Voluntis S.A. announced today the introduction of CoaguChek(R) Link, a
versatile online resource that helps simplify and streamline the process of
managing patients on anticoagulation therapy.

The web-based application gives patients who self-test their PT/INR (clotting
time) a simple, convenient way to report their test results and gives doctors a
single, secure site to access data to more effectively monitor and manage their
patients on warfarin therapy. It is available to physicians who prescribe a
patient self-testing program through CoaguChek Patient Services (CPS), an
Independent Diagnostic Testing Facility that provides support services for
physicians and their patients. The application is based on the Medpassport
platform developed by Voluntis, a healthcare software company specializing in
Patient Relationship Management.

“CoaguChek Link helps doctors and their patients stay connected so they can work
together to manage the patient’s anticoagulation therapy more effectively,
whether the patient is at home or away,” said Tim Huston, director of marketing,
professional diagnostics at Roche Diagnostics Corporation. “It simplifies the
process for everyone, facilitates better therapy management, and contributes to
the goal of helping improve patient outcomes.”

CoaguChek Link offers healthcare providers a convenient patient management
resource, helping to simplify documentation and streamline office workflow so
they can focus on patients that require follow-up care. Clinics and physician
offices can use the application (coagucheklink.com) to quickly enroll patients
with CPS, educate them about their therapy, view test results in real time
through a password-protected portal, modify recommended test frequency or
acceptable ranges for patient test results, and generally access the information
needed to monitor and adjust a patient’s anticoagulant therapy from anywhere. If
a patient doesn’t report results according to schedule or the results are
outside of the range the doctor specifies, the system automatically flags it and
the patient’s healthcare provider and CPS clinical specialists are notified.

The patient portal of CoaguChek Link helps empower patients to take a more
active role in their anticoagulation therapy. At their convenience, enrolled
patients can simply log in to the site to report their test results, order
supplies, update their profile information, or learn more about their own
therapy and the importance of testing.

“CoaguChek Link will give our healthcare providers greater flexibility and an
expanded range of options,” said Howard Sams, director of business operations at
CoaguChek Patient Services. “It will help streamline and simplify the process of
monitoring test results, which can help free up physicians to focus on managing
patient therapy more effectively.”

“We are delighted to have the opportunity to contribute to the continued success
of CoaguChek Patient Services in the USA,” said Pierre Leurent, Founder and CEO
of Voluntis. “This program exemplifies our vision for Voluntis solutions:
leading-edge, proven and secure technologies that have the potential to help
improve patient care.”

About CoaguChek Patient Services

CoaguChek Patient Services (CPS) is an Independent Diagnostic Testing Facility
(IDTF) that provides comprehensive support services for healthcare providers and
their anticoagulation patients who perform self-testing. CPS is part of Roche
Insulin Delivery Systems, which is accredited by the Joint Commission and has
received its Gold Seal of Approval(TM) for complying with the highest national
standards for safety and quality of care.

About Voluntis

Voluntis is a healthcare software company specialized in Patient Relationship
Management (PRM), its flagship product is called Medpassport. Its mission is to
empower healthcare organizations (pharmaceutical and medical companies, insurers
and employers, healthcare service providers) to deliver outstanding patient
monitoring and support services, using state-of-the-art information and
communication technologies. Since 2003, Medpassport has been deployed in Europe
and the USA, to manage over 550,000 patient records in over 15 therapeutic
areas, including diabetes, respiratory and cardiovascular diseases, oncology,
nutrition and sports medicine. Voluntis is a certified ISO 9001:2008 and ISO
13485:2003 company. Voluntis is headquartered in Paris, France, and has offices
in Washington DC, USA. To learn more: www.voluntis.com/?lang=en.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is
the world’s largest biotech company with truly differentiated medicines in
oncology, virology, inflammation, metabolism and CNS. Roche is also the world
leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in
diabetes management. Roche’s personalized healthcare strategy aims at providing
medicines and diagnostic tools that enable tangible improvements in the health,
quality of life and survival of patients. In 2009, Roche had over 80,000
employees worldwide and invested almost 10 billion Swiss francs in R&D. The
Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a
wholly owned member of the Roche Group. Roche has a majority stake in Chugai
Pharmaceutical, Japan. For more information: www.roche.com or
www.roche-diagnostics.us.

Coagucheklink.com does not provide automated treatment decisions and is not a
substitute for professional medical advice.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:
Roche
Betsy Cox
Director, Corporate Communications
Roche Diagnostics Corporation
Indianapolis, IN, USA
(317) 521-3911
betsy.cox@roche.com

Voluntis
Manon Chevassut / Gaelle Ryouq
Media Relations, Presse-Papiers Agency
+33 (0)1 46 99 69 62
manon.chevassut@pressepapiers.fr / gaelle.ryouq@pressepapiers.fr